16 November 2026
by Jeff Craven

Recon: FDA rejects ivonescimab for lung cancer indication; J&J to buy eye disease biotech Ollin Biosciences for up to $3.3B

Recon-RF-Dept-380x215.png

Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.

In Focus: US
  • FDA rejects Summit, Akeso's ivonescimab in narrow lung cancer setting (Endpoints) (STAT)
  • AstraZeneca gets US nod for expanded Imfinzi use, new rare-disease therapy (Reuters)
  • FDA approves at-home use of BioXcel's agitation drug (Reuters)
  • Klygefa approved in the USA and EU for gMG (The Pharma Letter)
  • Kamau’s gene-corrected sickle cell therapy nula-cel gets FDA RMAT designation on three-patient data (The Pharma Letter)
  • FDA, sponsors still not aligned on streamlined preclinical programs (Pink Sheet)
  • US has lost measles elimination status, global health authorities say (NPR) (Wall Street Journal)
  • Sandoz launches Eylea biosimilar Enzeevu in US (The Pharma Letter)
  • FDA relied on real-world evidence for Gilead’s Hepcludex before, after approval (Pink Sheet)
  • Faster Clinical Trials Act’s bipartisan backing could bolster FDA user fee package bid (Pink Sheet)
In Focus: International
  • AstraZeneca pulls EU filing for antibody as CHMP backs Gazyvaro in lupus (Endpoints)
  • Europe's CHMP backs Baxfendy, gives Hansoh's Aumseqa another chance (Fierce Pharma)
  • Novo's haemophilia drug gets EU approval (Reuters)
  • Zybrivo wins EMA nod but faces a crowded, Keytruda-dominated EU market (Pink Sheet)
  • What Ojemda teaches drugmakers about using JCA reports in Germany (Pink Sheet)
  • Companies seek right to be consulted before EU requires drug repurposing (Pink Sheet)
  • KemSu sponsors plot EU resubmission as Meplyffa hits another roadblock (Pink Sheet)
  • Aumseqa’s EU comeback begins just seven weeks after unprecedented revocation (Pink Sheet)
  • Their loss, our gain? Canada makes its case to Europe amid US instability (BioSpace)
  • China’s pharma industry wants to go global. The US could get in its way (PharmaVoice)
Pharma & Biotech
  • J&J to buy eye disease biotech Ollin Biosciences for up to $3.3B (Endpoints) (Reuters)
  • Lilly adds to buyout streak with $1.5B purchase of startup Calytrix (BioPharma Dive) (Bloomberg)
  • Rising costs leave 9 in 10 new medicines unprofitable, IQVIA finds (BioSpace)
  • Sofinnova amasses €725M for late-stage European biotechs (Endpoints)
  • CG Oncology's immunotherapy reduces risk of tumor recurrence in bladder cancer trial (Reuters) (Endpoints)
  • Argenx is spending billions to push beyond Vyvgart (Endpoints)
  • Windward Bio hits Nasdaq with $175M IPO, plus another $50M from Sanofi (Endpoints)
  • Helus’ psychedelic drug improved depression in study but faces safety questions (STAT)
  • Moderna readies commercial cancer vaccine production ahead of FDA filing (Endpoints)
  • New antihypertensives face access hurdles competing against established generics (Pink Sheet)
Medtech
  • FDA posts early alerts for two product removals (MedTech Dive)
  • Olympus making strides on FDA quality concerns, CEO says (MedTech Dive)
  • Medtech regulators push for whole-lifecycle monitoring in 2027 (Medtech Insight)
  • Terumo lowers FY guidance as RelayPro recall scope widens (Medtech Insight)
  • Medtech majors favor spin-offs and tuck-ins over big buys on Q3 earnings calls (Medtech Insight)
  • CMS expands outpatient surgery coverage, approves nine devices in 2027 hospital payment final rule (Medtech Insight)
Food & Nutrition
Government & Legal
  • Teva settles US states' drug price-fixing case (Reuters)
  • HHS funnels funding and research toward ibogaine and other psychedelics, with Mark Cuban’s help (Endpoints)
  • Senators introduce bill to curb conflicts of interest on preventive care panel (STAT)
  • Enforcement of stringent Medicaid work requirements delayed for six months (STAT)
  • Bipartisan push possible to curb Trump tariffs (MedTech Dive)
  • Democrats coalesce around ‘Medicare for More,’ ‘Medikids’ proposals (STAT)
  • Senator-elect Abdul El-Sayed on restoring trust in science, the state of public health, and RFK Jr. (STAT)

Regulatory Recon is our regular intelligence briefing for the regulatory affairs space, bringing you the top regulatory, biopharma and medtech news stories from around the globe. Regulatory Recon is published each week on Monday, Tuesday and Thursday.

A story’s inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.